<DOC>
	<DOCNO>NCT00527137</DOCNO>
	<brief_summary>Open-label , randomize study NESP pediatric subject 18 year age young . Subjects receive study drug ( NESP rHuEPO ) 28 week 2 week screen baseline period . During study , procedure include bloodwork laboratory assessment vital sign . Dose titration determine hemoglobin value take weekly study . Antibody sample take baseline end study assessment . A physical examination laboratory test conclude study .</brief_summary>
	<brief_title>NESP Pediatric Study</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 18 year age ESRD receive dialysis CRI eGFR less 30 mL/min Baseline hemoglobin 9.5 12.5 g/dL iron replete Stable rHuEPO therapy 8 week Scheduled livingrelated kidney transplant Uncontrolled blood pressure seizure activity Hyperparathyroidism Major surgery within 12 week active inflammatory disease Currently receive antibiotic Clinical evidence malignancy Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>